Clinical Trials Directory

Trials / Enrolling By Invitation

Enrolling By InvitationNCT04677699

Combined Antibody Screening for Celiac and Diabetes Evaluation

Status
Enrolling By Invitation
Phase
Study type
Observational
Enrollment
64,410 (estimated)
Sponsor
Pacific Northwest Research Institute · Academic / Other
Sex
All
Age
1 Day – 7 Years
Healthy volunteers
Accepted

Summary

The CASCADE Study (Combined Antibody Screening for Celiac and Diabetes Evaluation) is an observational study whose primary goal is to show that population-based screening for advanced prediction of type 1 diabetes (T1D) and celiac disease (CD) is feasible to prevent diabetic ketoacidosis (DKA), improve celiac disease diagnosis, and ultimately gain public health acceptance to facilitate future prevention. It has two arms, a Birth Cohort and a Kids (cross sectional) Cohort.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTCombined Risk ScoreSeveral factors will be analyzed to assign each subject combined risk score. This will assess the subject's risk of developing Type 1 Diabetes and/or Celiac Disease.

Timeline

Start date
2020-12-01
Primary completion
2022-12-01
Completion
2026-06-01
First posted
2020-12-21
Last updated
2020-12-21

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT04677699. Inclusion in this directory is not an endorsement.